REGN 14284
Alternative Names: REGN-14284Latest Information Update: 08 Aug 2023
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 30 May 2023 Regeneron Pharmaceuticals completed a phase-I trial in COVID-2019 infections (In volunteers) in Belgium (IV, SC) (NCT05505448)
- 15 Sep 2022 Phase-I clinical trials in COVID-2019 infections (In volunteers) in Belgium (IV) (NCT05505448)
- 15 Sep 2022 Phase-I clinical trials in COVID-2019 infections (In volunteers) in Belgium (SC) (NCT05505448)